FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896733778> ?p ?o ?g. }

• W2896733778 abstract "Previous studies have demonstrated that left-sided tumors have better prognoses than right-sided tumors in RAS wild-type mCRC (metastatic colorectal cancer) patients, while anti-EGFR mAbs appear to have no advantage compared with bevacizumab for right-sided tumors in these patients. Nevertheless, it remains unclear whether primary tumor location affects patients’ options for potentially curative resection. PubMed, the Cochrane Library, Embase, ASCO, and ESMO conference abstracts were searched. The inclusion criteria were RCT (randomized controlled trials) studies that evaluated the efficacy of anti-EGFR mAbs based on primary tumor location. The outcomes included ORR, ETS, and DpR. ORs for ORR were calculated with 95% confidence intervals by Comprehensive Meta-Analysis, version 2.0. Nine studies including nine RCTs were analyzed. Regardless of left- or right-sided tumors, the ORRs for anti-EGFR mAb (left-sided: 80.2%, 95% CI, 47–95%; I2 = 76.9%; right-sided: 46.1%, 95% CI, 39.4–53.0%; I2 = 18.9%) were both higher than the control arm including chemotherapy with or without bevacizumab. The ORs for anti-EGFR mAbs have a significant benefit compared with chemotherapy with or without bevacizumab in left-sided tumors (OR = 2.19, 95% CI, 1.41–3.38; P < 0.001). For right-sided tumors, anti-EGFR mAbs still significantly improved the ORR compared with chemotherapy alone (OR = 1.75, 95% CI, 1.05–2.90; P = 0.03), and the OR numerically favored the anti-EGFR mAbs compared with bevacizumab (OR = 1.281, 95% CI, 0.77–2.12; P = 0.335). The data of ETS and DpR from three RCTs also favored the EGFR antibody irrespective of tumor location. Resection data on differentiating tumor locations is inconclusive. For right-sided tumors, it should be noted that median PFS and OS were comparable for patients who achieved ETS in both treatment arms. Anti-EGFR mAbs have advantages in the tumor shrinkage regardless of left- or right-sided tumors, which is important for conversion therapy. For right-sided tumors, anti-EGFR mAbs should remain the first choice for potentially curative resection in RAS wild-type mCRC patients. ETS may represent a subgroup of patients with right-sided tumors who might benefit from the anti-EGFR mAb." @default.
• W2896733778 created "2018-10-26" @default.
• W2896733778 creator A5016245266 @default.
• W2896733778 creator A5034347994 @default.
• W2896733778 creator A5034551921 @default.
• W2896733778 creator A5038578925 @default.
• W2896733778 creator A5042100539 @default.
• W2896733778 creator A5071880678 @default.
• W2896733778 creator A5079555269 @default.
• W2896733778 date "2018-10-08" @default.
• W2896733778 modified "2023-10-03" @default.
• W2896733778 title "Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis" @default.
• W2896733778 cites W1933451634 @default.
• W2896733778 cites W1934094702 @default.
• W2896733778 cites W2019387807 @default.
• W2896733778 cites W2023807845 @default.
• W2896733778 cites W2060189595 @default.
• W2896733778 cites W2066040529 @default.
• W2896733778 cites W2066390717 @default.
• W2896733778 cites W2110803737 @default.
• W2896733778 cites W2113029107 @default.
• W2896733778 cites W2114857812 @default.
• W2896733778 cites W2123548341 @default.
• W2896733778 cites W2125877119 @default.
• W2896733778 cites W2129998117 @default.
• W2896733778 cites W2132545630 @default.
• W2896733778 cites W2143743735 @default.
• W2896733778 cites W2156775359 @default.
• W2896733778 cites W2157769714 @default.
• W2896733778 cites W2161817637 @default.
• W2896733778 cites W2164799457 @default.
• W2896733778 cites W2167877099 @default.
• W2896733778 cites W2262414037 @default.
• W2896733778 cites W2345744951 @default.
• W2896733778 cites W2411708874 @default.
• W2896733778 cites W2507605347 @default.
• W2896733778 cites W2509067245 @default.
• W2896733778 cites W2528475762 @default.
• W2896733778 cites W2531319683 @default.
• W2896733778 cites W2558788971 @default.
• W2896733778 cites W2589677705 @default.
• W2896733778 cites W2590442063 @default.
• W2896733778 cites W2599059217 @default.
• W2896733778 cites W2601885110 @default.
• W2896733778 cites W2605964154 @default.
• W2896733778 cites W2609363527 @default.
• W2896733778 cites W2611122055 @default.
• W2896733778 cites W2617982897 @default.
• W2896733778 cites W2636687439 @default.
• W2896733778 cites W2743762778 @default.
• W2896733778 cites W2765766854 @default.
• W2896733778 cites W2879208650 @default.
• W2896733778 cites W2890252509 @default.
• W2896733778 doi "https://doi.org/10.1186/s12957-018-1502-7" @default.
• W2896733778 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6176519" @default.
• W2896733778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30296945" @default.
• W2896733778 hasPublicationYear "2018" @default.
• W2896733778 type Work @default.
• W2896733778 sameAs 2896733778 @default.
• W2896733778 citedByCount "3" @default.
• W2896733778 countsByYear W28967337782020 @default.
• W2896733778 crossrefType "journal-article" @default.
• W2896733778 hasAuthorship W2896733778A5016245266 @default.
• W2896733778 hasAuthorship W2896733778A5034347994 @default.
• W2896733778 hasAuthorship W2896733778A5034551921 @default.
• W2896733778 hasAuthorship W2896733778A5038578925 @default.
• W2896733778 hasAuthorship W2896733778A5042100539 @default.
• W2896733778 hasAuthorship W2896733778A5071880678 @default.
• W2896733778 hasAuthorship W2896733778A5079555269 @default.
• W2896733778 hasBestOaLocation W28967337781 @default.
• W2896733778 hasConcept C121608353 @default.
• W2896733778 hasConcept C126322002 @default.
• W2896733778 hasConcept C141071460 @default.
• W2896733778 hasConcept C143998085 @default.
• W2896733778 hasConcept C168563851 @default.
• W2896733778 hasConcept C2776478404 @default.
• W2896733778 hasConcept C2776694085 @default.
• W2896733778 hasConcept C2777802072 @default.
• W2896733778 hasConcept C2779013556 @default.
• W2896733778 hasConcept C2779998722 @default.
• W2896733778 hasConcept C2780140570 @default.
• W2896733778 hasConcept C2780283643 @default.
• W2896733778 hasConcept C44249647 @default.
• W2896733778 hasConcept C526805850 @default.
• W2896733778 hasConcept C71924100 @default.
• W2896733778 hasConcept C90924648 @default.
• W2896733778 hasConcept C95190672 @default.
• W2896733778 hasConceptScore W2896733778C121608353 @default.
• W2896733778 hasConceptScore W2896733778C126322002 @default.
• W2896733778 hasConceptScore W2896733778C141071460 @default.
• W2896733778 hasConceptScore W2896733778C143998085 @default.
• W2896733778 hasConceptScore W2896733778C168563851 @default.
• W2896733778 hasConceptScore W2896733778C2776478404 @default.
• W2896733778 hasConceptScore W2896733778C2776694085 @default.
• W2896733778 hasConceptScore W2896733778C2777802072 @default.
• W2896733778 hasConceptScore W2896733778C2779013556 @default.
• W2896733778 hasConceptScore W2896733778C2779998722 @default.
• W2896733778 hasConceptScore W2896733778C2780140570 @default.
• W2896733778 hasConceptScore W2896733778C2780283643 @default.
• W2896733778 hasConceptScore W2896733778C44249647 @default.

• next